# Pfizer: Observational study completed, 50 enrolled (Non-Small Cell Lung Cancer ALK-positive)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Pfizer |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC |
| NCT ID | NCT07556549 |
| Phase | Observational |
| Status | completed |
| Conditions | Non-Small Cell Lung Cancer ALK-positive |
| Intervention types | drug |
| Target enrollment | 50 |
| Site countries | China |
| Posted | 2026-04-29 |
| Planned start | 2026-05-18 |
| Event | Completed |
| Event date | 2026-09-24 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07556549). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.